Pharminent · Daily Brief
FDA approves Roche’s oral SERD Wilserdly for breast cancer
The FDA approved Roche’s Wilserdly, an oral selective estrogen receptor degrader for breast cancer, bringing the company into the US oral SERD market.
Pharmaphorum →$RHHBYFDA rejects Summit and Akeso’s ivonescimab in EGFR lung cancer
The FDA declined to approve the PD-1/VEGF bispecific ivonescimab in a form of EGFR-mutated lung cancer, citing the drug’s failure to initially extend survival. Summit’s shares fell on the decision.
BioPharma Dive →FDA approves Klygefa, Gazyva and Igalmi in three indications
The FDA approved Klygefa for generalized myasthenia gravis, Gazyva for primary membranous nephropathy, and Igalmi for agitation associated with schizophrenia.
PharmExec →CG Oncology’s cretostimogene cuts bladder cancer recurrence risk 68%
CG Oncology reported that cretostimogene reduced the risk of recurrence by 68% when given after surgery in a bladder cancer trial, surpassing Wall Street expectations and lifting the company’s shares.
BioPharma Dive →Novo reports Wegovy reduced BMI in children aged six to 12
Novo published results from a trial of Wegovy injection in children aged six to 12 with obesity, showing the drug reduced their BMI.
Pharmaphorum →$NVOHelus shares fall on phase 3 psychedelic depression data
Helus released data from a phase 3 trial of HLP003 showing evidence of efficacy in depression, and its shares fell on safety concerns.
Pharmaphorum →Sellas’ blood cancer immunotherapy reduces risk of death in trial
Sellas reported that its experimental blood cancer immunotherapy reduced the risk of death in a clinical trial.
STAT →J&J to buy Ollin Biosciences for up to $3.3B
Johnson & Johnson agreed to acquire ophthalmology specialist Ollin Biosciences in a deal worth up to $3.3 billion, adding a bispecific antibody in Phase 3 development for wet age-related macular degeneration and diabetic macular edema.
Pharmaceutical Technology →$JNJLilly to acquire Calytrix Bio in deal worth up to $1.5B
Eli Lilly agreed to acquire Calytrix Bio in a transaction valued at up to $1.5 billion, gaining an investigational biparatopic antibody targeting mCALR-driven essential thrombocythemia and myelofibrosis.
Pharmaceutical Technology →$LLYSanofi and Seawolf sign licensing deal worth up to $1.2B
Seawolf Therapeutics and Sanofi signed a multi-target research partnership and exclusive licensing agreement worth up to $1.2 billion to develop treatments for bleeding disorders and other undisclosed indications.
Pharmaceutical Technology →$SNYMarrow Therapeutics raises $173M for sickle cell, beta thalassemia
Marrow Therapeutics has $173 million in venture funding to develop a treatment for sickle cell disease and beta thalassemia that it positions as a more accessible alternative to gene therapy and gene editing.
BioPharma Dive →Get the signal in your inbox
Sign up free →Pharminent — Competitive Intelligence Suite · Tickers link to Yahoo Finance for reference only. Editorial framings are analysis, not investment advice. © 2026.